A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.

Trial Details

NCT ID
NCT07205822
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Dato-DXd
Locations (sample)
  • Largo, Florida, United States|27.90979,-82.78842
  • Fort Wayne, Indiana, United States|41.1306,-85.12886
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Participant must be ≥ 18 years (and above legal age) at the time of screening.
  • Inoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-posi…
  • Progressed on and not suitable for further endocrine therapy per investigator assessment.
  • ECOG performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to the first dose of study intervention.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →